Загрузка...
Elimination of a cholecystokinin receptor agonist “trigger” in an effort to develop positive allosteric modulators without intrinsic agonist activity
Cholecystokinin (CCK) acts at the type 1 cholecystokinin receptor (CCK1R) to elicit satiety and is a well-established drug target for obesity. To date, small molecule agonists have been developed, but have failed to demonstrate adequate efficacy in clinical trials, and concerns about side effects an...
Сохранить в:
| Опубликовано в: : | Bioorg Med Chem Lett |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4408270/ https://ncbi.nlm.nih.gov/pubmed/25862198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2015.03.051 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|